key: cord-0756926-asgemh10
authors: Hsieh, Yu‐Cheng
title: Editorial to "Atrial fibrillation and the risk of 30‐day incident thromboembolic events and mortality in adults ≥50 years with COVID‐19"
date: 2020-12-03
journal: J Arrhythm
DOI: 10.1002/joa3.12477
sha: e82f483c33f763f3fa12962b0430bdc9378c1b9a
doc_id: 756926
cord_uid: asgemh10

nan

high risk of thrombosis both in the venous and arterial circulations. 1 The thromboembolism risk caused by COVID-19 in patients with AF comparing to AF patients without COVID-19 remains to be explored.

By using a global research network and propensity score matched over 13,000 adults with COVID-19, Harrison et al in this issue reported that the survival probability was significantly lower in adults with COVID-19 and AF compared to matched adults without AF (risk ratio 1.61), and risk of thromboembolic events was also higher in patients with AF (risk ratio 1.41). These findings indicated that AF remains a risk marker for increased all-cause mortality and thromboembolic events. Furthermore, the survival probability was significantly lower for adults with AF and COVID-19 compared to adults with AF while without COVID-19. Interestingly, there was no significant difference in risk of thromboembolic events between AF patients with and without COVID-19. The authors recommended that AF might be an important risk factor for inclusion in risk modeling and subsequent stratification of adults with COVID-19, and a target for intervention strategies.

This study firstly elucidated the association of AF on mortality and thromboembolic events in patients with COVID-19. However, several limitations of this study remain to be investigated. Firstly, the 30-day mortality rates were extremely high (82.7% in non-AF cohort and 88.3% in AF cohort) comparing to those reported by Therefore, it is speculated that elevated serum levels of Inflammatory cytokines including C-reactive protein, interleukin-6, and tumor necrosis factor-α caused by SARS-CoV-2 might mutually contribute to myocardial injury, AF genesis, thromboembolic events, and mortally.

With the findings from this study, optimal management of AF in patients with COVID-19 might be necessary to improve outcomes of patients with COVID-19 and AF. A major concern in this scenario is that all antiarrhythmic drugs (AADs) for rate/rhythm control may have significant side effects due to drug-drug interactions with emerging COVID-19 pharmacotherapy, leading to increased risk for bradycardia or tachyarrhythmias. Furthermore, drug-drug interaction between anti-coagulants and COVID-19 pharmacotherapy might lead to inadequate coagulation or bleeding events. Guideline for the management of AF in patients with COVID-19 has been published, which includes considerations of important potential drug-drug interactions of anticoagulants and AADs with emerging COVID-19 pharmacotherapies. 5 Clinicians should be aware of the indications/contraindications and major drug-drug interactions among AADs, anticoagulants, and emerging COVID-19 treatments in AF patients with COVID-19 to improve their clinical outcomes.

This study was supported in part by grants from Taichung Veterans General Hospital, Taiwan (TCVGH-NHRI10603, TCVGH-1067310C,   TCVGH-FCU1068205, TCVGH-YM1060201, TCVGH-VTA106PREM1,   TCVGH-1033103C, TCVGH-1033105C, TCVGH-1043109C, TCVGH-1053108C, TCVGH This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Guidance on acute management of atrial fibrillation in COVID-19